Daniel V Labarbera

List of Publications by Year
in descending order

31 papers	1,543 citations	516710 16 h-index	414414 32 g-index
32 all docs	32 docs citations	32 times ranked	2953 citing authors

#	Article	IF	Citations
1	Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. Journal of Medicinal Chemistry, 2022, 65, 3943-3961.	6.4	3
2	Oxidative stress as a candidate mechanism for accelerated neuroectodermal differentiation due to trisomy 21. Free Radical Biology and Medicine, 2022, 186, 32-42.	2.9	3
3	Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Molecular Carcinogenesis, 2021, 60, 201-212.	2.7	15
4	Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer. Oncogene, 2021, 40, 2884-2897.	5.9	13
5	TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	24
6	Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS Discovery, 2020, 25, 734-743.	2.7	13
7	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 1598-1612.	4.1	19
8	High Throughput Screen Identifies the DNMT1 (DNA Methyltransferase-1) Inhibitor, 5-Azacytidine, as a Potent Inducer of PTEN (Phosphatase and Tensin Homolog). Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1854-1869.	2.4	16
9	Drug Design Targeting T-Cell Factor-Driven Epithelialâ€“Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. Journal of Medicinal Chemistry, 2019, 62, 10182-10203.	6.4	12
10	Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment. Scientific Reports, 2019, 9, 301.	3.3	10
11	Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Molecular Cancer Research, 2019, 17, 1036-1048.	3.4	10
12	Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA capping enzyme. Antiviral Research, 2018, 154, 124-131.	4.1	46
13	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clinical Cancer Research, 2018, 24, 3059-3068.	7.0	366
14	Inhibition of Î±-glucosidase, Î±-amylase, and aldose reductase by potato polyphenolic compounds. PLoS ONE, 2018, 13, e0191025.	2.5	162
15	Larrea tridentata: A novel source for anti-parasitic agents active against Entamoeba histolytica, Giardia lamblia and Naegleria fowleri. PLoS Neglected Tropical Diseases, 2017, 11, e0005832.	3.0	30
16	Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract. Journal of Natural Products, 2016, 79, 1439-1444.	3.0	26
17	Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities. Journal of Medicinal Chemistry, 2016, 59, 480-485.	6.4	17
18	High-throughput imaging: Focusing in on drug discovery in 3D. Methods, 2016, 96, 97-102.	3.8	95

#	Article	IF	Citations
19	Aldose reductase inhibition alleviates hyperglycemic effects on human retinal pigment epithelial cells. Chemico-Biological Interactions, 2015, 234, 254-260.	4.0	41
20	Live Multicellular Tumor Spheroid Models For High-Content Imaging and Screening In Cancer Drug Discovery. Current Chemical Genomics and Translational Medicine, 2014, 8, 27-35.	4.3	35
21	The Characterization and Therapeutic Development of Natural Products from E. Officinalis: An Ayurvedic Medicinal Plant Used to Treat Diabetic Eye Disease. Journal of Alternative and Complementary Medicine, 2014, 20, A26-A26.	2.1	1
22	An Improved High Yield Total Synthesis and Cytotoxicity Study of the Marine Alkaloid Neoamphimedine: An ATP-Competitive Inhibitor of Topoisomerase IIÎ± and Potent Anticancer Agent. Marine Drugs, 2014, 12, 4833-4850.	4.6	10
23	The Synthesis of Vinylogous Amidine Heterocycles. Journal of Organic Chemistry, 2013, 78, 11887-11895.	3.2	10
24	Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties. Hormones and Cancer, 2013, 4, 36-49.	4.9	38
25	The Isolation and Characterization of Î²-Glucogallin as a Novel Aldose Reductase Inhibitor from Emblica officinalis. PLoS ONE, 2012, 7, e31399.	2.5	88
26	A High-Content Assay to Identify Small-Molecule Modulators of a Cancer Stem Cell Population in Luminal Breast Cancer. Journal of Biomolecular Screening, 2012, 17, 1211-1220.	2.6	14
27	The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opinion on Drug Discovery, 2012, 7, 819-830.	5.0	215
28	3D Models of Epithelial-Mesenchymal Transition in Breast Cancer Metastasis: High-Throughput Screening Assay Development, Validation, and Pilot Screen. Journal of Biomolecular Screening, 2011, 16, 141-154.	2.6	120
29	Neoamphimedine Circumvents Metnase-Enhanced DNA Topoisomerase IIÎ± Activity Through ATP-Competitive Inhibition. Marine Drugs, 2011, 9, 2397-2408.	4.6	19
30	The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anti-Cancer Drugs, 2009, 20, 425-436.	1.4	41
31	The Total Synthesis of Neoamphimedine. Journal of Organic Chemistry, 2007, 72, 8501-8505.	3.2	28